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Worldwide, more than 30 million people spend time 
in prison every year.1 The USA incarcerates 25% of 
these people and one in 31 Americans is currently 
under correctional control, either in jail, prison, or on 
probation or parole.2 Most prisoners will eventually 
be released, and the 2 weeks after release have been 
shown to be associated with a substantial increase in 
mortality, especially from overdose.3 Substance use 
disorders are highly prevalent among incarcerated 
populations, with more than half of prisoners in 
some countries being imprisoned for drug-related 
convictions.4 In the USA, 85% of people in prisons or 
jails are substance involved, with 1·5 million individuals 
meeting DSM criteria for a substance use disorder 
and an additional 458 000 either with a history of 
substance use, under the inﬂ uence at the time of arrest, 
or convicted of a crime committed to obtain money to 
buy drugs.5
Addiction is a treatable disease and decades of 
scientiﬁ c evidence support the eﬃ  cacy of treatment 
to improve clinical outcomes, save lives, and reduce 
societal costs. Treatment for opioid use disorder during 
incarceration with agonists such as buprenorphine 
or methadone has been shown to reduce recidivism, 
improve treatment retention, reduce illicit drug use, 
and decrease criminal activity.6,7 Buprenorphine has 
also been shown to decrease the risk of overdose 
death by more than 50%.8 However, despite the 
overwhelming evidence, treatment remains variable 
between correctional facilities and few prisoners 
receive these life-saving drugs.9  
In The Lancet Psychiatry, Zheng Chang and col-
leagues10 examined mortality in all people released 
from prison in Sweden between Jan 1, 2000, and 
Dec 31, 2009. In this sample of 47 326 individuals and 
238 457 person-years of follow-up, the researchers 
reported that substance use (both alcohol and illicit 
drug use) was related to a substantial proportion of 
post-release mortality, even when controlling for 
other factors using imprisoned siblings as controls. 
The association between mental illness and post-
release mortality disappeared when substance use was 
controlled for. This well designed study of an entire 
country oﬀ ers important and concerning new data on 
the high risk of death for individuals with substance 
use disorder who are incarcerated. The results of the 
study also showed that the period of risk of increased 
mortality after release from prison is much longer—
months to years—than the few weeks previously 
reported,3 an important ﬁ nding that is probably true 
in most places. These ﬁ ndings are even more alarming 
when considering the magnitude of risk for a country 
such as the USA, which has a much higher incarceration 
rate and far more drug-related convictions than does 
Sweden. 
Access to eﬀ ective treatments for addiction, 
particularly pharmacotherapy, is the single greatest 
intervention that can reduce the death toll from 
overdose.11 The withholding of evidence-based 
treatment for prisoners is arguably unethical and 
certainly unwise. In the USA, correctional facilities 
are mandated by the Supreme Court to provide 
medical care that meets the community standard.12 
And yet, within state prisons people with drug use 
disorders largely go without care: of these people, 
only 0·8% receive detoxiﬁ cation services, 0·3% 
receive maintenance pharmacotherapy, 6·5% receive 
counselling by a pro fessional, and 9·5% receive 
treatment in a residential facility.13 Even those on 
treatment in the community are systematically 
forced oﬀ  when incarcerated, with detrimental 
consequences.14 The absence of care in this deeply 
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There is no health without mental health. This will be 
one of my themes when I assume the role of president 
of the American Psychiatric Association (APA) in May, 
2015. The passage of the Mental Health Parity and 
Addiction Equity Act in 2008 and of the Aﬀ ordable 
Care Act in 2010 provides Americans with the largest 
expansion of health coverage for mental health 
and substance use disorders in a generation.1 This 
means that treatment for conditions such as anxiety, 
depression, and post-traumatic stress disorder (PTSD) 
are now considered essential health beneﬁ ts. However, 
many barriers remain in the quest to obtain true 
parity for our patients who have mental health and 
substance use disorders. 
One of the primary barriers is the stigma associated 
with mental illness and substance misuse.2 Studies 
show that 25% of all US adults, about 61·5 million 
Americans, have a mental disorder in a given year.3 
Nevertheless, many members of the public are 
reluctant to admit that these statistics apply to 
them or their family members because of the stigma 
attached to having a mental illness. Even when mental 
health services are available, stigma can lead to 
reluctance to seek treatment. 
Another barrier to obtaining mental health care 
is the fragmentation of mental health and other 
medical services in the USA.4 The APA is advocating 
new models of delivery of mental health care in 
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aﬀ ected population translates into high costs to society 
and the communities that these individuals return to. 
As the Article shows, these costs also translate into 
avoidable deaths from a treatable illness. 
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